E
Erlend B. Smeland
Researcher at Oslo University Hospital
Publications - 178
Citations - 22486
Erlend B. Smeland is an academic researcher from Oslo University Hospital. The author has contributed to research in topics: Antigen & Diffuse large B-cell lymphoma. The author has an hindex of 55, co-authored 173 publications receiving 20797 citations. Previous affiliations of Erlend B. Smeland include National Institutes of Health & University of Oslo.
Papers
More filters
Journal ArticleDOI
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
Andreas Rosenwald,George E. Wright,Wing C. Chan,Wing C. Chan,Joseph M. Connors,Elias Campo,Richard I. Fisher,Randy D. Gascoyne,H. Konrad Muller-Hermelink,Erlend B. Smeland,Jena M. Giltnane,Elaine M. Hurt,Hong Zhao,Lauren Averett,Liming Yang,Wyndham H. Wilson,Elaine S. Jaffe,Richard M. Simon,Richard D. Klausner,John Powell,P L Duffey,Dan L. Longo,Timothy C. Greiner,Dennis D. Weisenburger,Warren G. Sanger,Bhavana J. Dave,James C. Lynch,Julie M. Vose,James O. Armitage,Emilio Montserrat,Armando López-Guillermo,Thomas M. Grogan,Thomas P. Miller,Michel Leblanc,German Ott,Stein Kvaløy,Jan Delabie,Harald Holte,Peter Krajci,Trond Stokke,Louis M. Staudt +40 more
TL;DR: DNA microarrays can be used to formulate a molecular predictor of survival after chemotherapy for diffuse large-B-cell lymphoma and this gene-based predictor and the international prognostic index were independent prognostic indicators.
Journal ArticleDOI
Stromal gene signatures in large-B-cell lymphomas
Georg Lenz,George E. Wright,Sandeep S. Dave,Wenming Xiao,Jonathan D. Powell,Hong Zhao,Weihong Xu,Bruce K. Tan,Neta Goldschmidt,Javeed Iqbal,Julie M. Vose,Martin Bast,Kai Fu,Dennis D. Weisenburger,Timothy C. Greiner,James O. Armitage,Alastair H. Kyle,Lorraine May,Randy D. Gascoyne,Joseph M. Connors,Gunhild Trøen,Harald Holte,Stein Kvaløy,Daan Dierickx,Gregor Verhoef,Jan Delabie,Erlend B. Smeland,Pedro Jares,A. Martinez,Armando López-Guillermo,Emili Montserrat,Elias Campo,Rita M. Braziel,Thomas P. Miller,Lisa M. Rimsza,James R. Cook,Brad Pohlman,John Sweetenham,Raymond R. Tubbs,Richard I. Fisher,Elena Hartmann,Andreas Rosenwald,German Ott,German Ott,H-K Muller-Hermelink,D Wrench,T. A. Lister,Elaine S. Jaffe,Wyndham H. Wilson,Wing C. Chan,Louis M. Staudt +50 more
TL;DR: Survival after treatment of diffuse large-B-cell lymphoma is influenced by differences in immune cells, fibrosis, and angiogenesis in the tumor microenvironment, and a multivariate model created from three gene-expression signatures predicted survival both in patients who received CHOP and patients who receive R-CHOP.
Journal ArticleDOI
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis,Vu N. Ngo,Georg Lenz,Pavel Tolar,Ryan M. Young,Paul B. Romesser,Holger Kohlhammer,Laurence Lamy,Hong Zhao,Yandan Yang,Weihong Xu,Arthur L. Shaffer,George E. Wright,Wenming Xiao,John Powell,Jian Kang Jiang,Craig J. Thomas,Andreas Rosenwald,German Ott,Hans K. Müller-Hermelink,Randy D. Gascoyne,Joseph M. Connors,Nathalie A. Johnson,Lisa M. Rimsza,Elias Campo,Elaine S. Jaffe,Wyndham H. Wilson,Jan Delabie,Erlend B. Smeland,Richard I. Fisher,Rita M. Braziel,Raymond R. Tubbs,James R. Cook,Dennis D. Weisenburger,Wing C. Chan,Susan K. Pierce,Louis M. Staudt +36 more
TL;DR: Findings establish chronic active BCR signalling as a new pathogenetic mechanism in ABC DLBCL, suggesting several therapeutic strategies.
Journal ArticleDOI
Oncogenically active MYD88 mutations in human lymphoma
Vu N. Ngo,Vu N. Ngo,Ryan M. Young,Roland Schmitz,Sameer Jhavar,Wenming Xiao,Kian-Huat Lim,Holger Kohlhammer,Weihong Xu,Yandan Yang,Hong Zhao,Arthur L. Shaffer,Paul B. Romesser,George E. Wright,John Powell,Andreas Rosenwald,Hans K. Müller-Hermelink,German Ott,Randy D. Gascoyne,Joseph M. Connors,Lisa M. Rimsza,Elias Campo,Elaine S. Jaffe,Jan Delabie,Erlend B. Smeland,Richard I. Fisher,Rita M. Braziel,Raymond R. Tubbs,James R. Cook,Denny D. Weisenburger,Wing C. Chan,Louis M. Staudt +31 more
TL;DR: The dependence of ABC DLBCLs on MYD88, an adaptor protein that mediates toll and interleukin (IL)-1 receptor signalling, is described and the development of inhibitors of IRAK4 kinase and other components of this pathway for the treatment of tumours bearing oncogenic MyD88 mutations are supported.
Journal ArticleDOI
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
Sandeep S. Dave,George E. Wright,Bruce K. Tan,Andreas Rosenwald,Andreas Rosenwald,Randy D. Gascoyne,Wing C. Chan,Richard I. Fisher,Rita M. Braziel,Lisa M. Rimsza,Thomas M. Grogan,Thomas P. Miller,Michael LeBlanc,Timothy C. Greiner,Dennis D. Weisenburger,James C. Lynch,Julie M. Vose,James O. Armitage,Erlend B. Smeland,Stein Kvaløy,Harald Holte,Jan Delabie,Joseph M. Connors,Peter M. Lansdorp,Qin Ouyang,T. Andrew Lister,Andrew Davies,Andrew J. Norton,H. Konrad Muller-Hermelink,German Ott,Elias Campo,Emilio Montserrat,Wyndham H. Wilson,Elaine S. Jaffe,Richard M. Simon,Liming Yang,John Powell,Hong Zhao,Neta Goldschmidt,Michael Chiorazzi,Louis M. Staudt +40 more
TL;DR: The length of survival among patients with follicular lymphoma correlates with the molecular features of nonmalignant immune cells present in the tumor at diagnosis.